BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 14637191)

  • 1. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
    Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T
    Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
    Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
    Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
    Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
    Yamazaki H; Nakajima M; Nakamura M; Asahi S; Shimada N; Gillam EM; Guengerich FP; Shimada T; Yokoi T
    Drug Metab Dispos; 1999 Sep; 27(9):999-1004. PubMed ID: 10460798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
    Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Saito T; Parkinson A; Nakagawa K; Kamataki T
    Xenobiotica; 2005 Jan; 35(1):69-83. PubMed ID: 15788369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
    Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
    Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.
    Stevens JC
    Drug Discov Today; 2006 May; 11(9-10):440-5. PubMed ID: 16635807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.
    Niwa T; Okamoto A; Narita K; Toyota M; Kato K; Kobayashi K; Sasaki S
    Arch Biochem Biophys; 2020 Mar; 682():108283. PubMed ID: 32001245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M; Shindo M; Shimada T
    Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells.
    Ohmori S; Nakasa H; Asanome K; Kurose Y; Ishii I; Hosokawa M; Kitada M
    Biochim Biophys Acta; 1998 May; 1380(3):297-304. PubMed ID: 9555064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
    Klees TM; Sheffels P; Dale O; Kharasch ED
    Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
    Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
    Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helices F-G are important for the substrate specificities of CYP3A7.
    Torimoto N; Ishii I; Toyama K; Hata M; Tanaka K; Shimomura H; Nakamura H; Ariyoshi N; Ohmori S; Kitada M
    Drug Metab Dispos; 2007 Mar; 35(3):484-92. PubMed ID: 17178770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.
    Lee AJ; Cai MX; Thomas PE; Conney AH; Zhu BT
    Endocrinology; 2003 Aug; 144(8):3382-98. PubMed ID: 12865317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
    Inui H; Maeda A; Ohkawa H
    Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
    Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
    Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
    Shen L; Fitzloff JF; Cook CS
    Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.